Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: A phase II study by the Intergroupe Francophone du Myélome

Journal of Clinical Oncology

Volumn 32, Issue 25, 2014, Pages 2712-2717

  Roussel, Murielle ^a   Lauwers Cances, Valérie ^a   Robillard, Nelly ^c   Hulin, Cyrille ^d   Leleu, Xavier ^e   Benboubker, Lotfi ^f   Marit, Gérald ^g   Moreau, Philippe ^c   Pegourie, Brigitte ^h   Caillot, Denis ⁱ   Fruchart, Christophe ⁱ   Stoppa, Anne Marie ^j   Gentil, Catherine ^a   Wuilleme, Soraya ^c   Huynh, Anne ^a   Hebraud, Benjamin ^a   Corre, Jill ^a   Chretien, Marie Lorraine ⁱ   Facon, Thierry ^e   Avet Loiseau, Hervé ^a   Attal, Michel ^b   more..

^a INSTITUT CLAUDIUS REGAUD   (France)

^b HÔTEL DIEU   (France)

^c CHU NANCY BRABOIS   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e CHU BRETONNEAU   (France)

^f HAUT LÉVÊQUE HOSPITAL   (France)

^g HÔPITAL MICHALLON   (France)

^h HÔPITAL DU BOCAGE   (France)

ⁱ CENTRE FRANÇOIS BACLESSE   (France)

^j INSTITUT PAOLI CALMETTES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELPHALAN; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE; THALIDOMIDE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BASAL CELL CARCINOMA; BONE PAIN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER SURVIVAL; CANCER THERAPY; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROCOLITIS; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; LIVER DISEASE; LUNG DISEASE; MAINTENANCE THERAPY; MALE; MINIMAL RESIDUAL DISEASE; MOOD DISORDER; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OPEN STUDY; OVERALL SURVIVAL; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; AUTOTRANSPLANTATION; CLINICAL TRIAL; FRANCE; MIDDLE AGED; PROCEDURES; REMISSION; STEM CELL TRANSPLANTATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COMBINED MODALITY THERAPY; CONSOLIDATION CHEMOTHERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS;

EID: 84906819363     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.8164     Document Type: Article

References (24)

1. Cavo M, Tacchetti P, Patriarca F, et al: Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study. Lancet 376:2075-2085, 2010
2. Moreau P, Avet-Loiseau H, Facon T, et al: Bortezomib plus dexamethasone versus reduceddose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 118:5752-5758, 2011
3. Rosiñol L, Oriol A, Teruel AI, et al: Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA/ GEM study. Blood 120:1589-1596, 2012
4. Reeder CB, Reece DE, Kukreti V, et al: Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial. Leukemia 23:1337-1341, 2009
5. Richardson PG, Weller E, Lonial S, et al: Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116:679-686, 2010
6. Cavo M, Pantani L, Petrucci MT, et al: Bortezomib-thalidomide- dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 120:9-19, 2012
7. Barlogie B, Tricot G, Rasmussen E, et al: Total therapy 2 without thalidomide in comparison with total therapy 1: Role of intensified induction and posttransplantation consolidation therapies. Blood 107:2633-2638, 2006
8. Attal M, Harousseau JL, Leyvraz S, et al: Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108:3289-3294, 2006
9. Spencer A, Prince HM, Roberts AW, et al: Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 27:1788-1793, 2009
10. Lokhorst HM, van der Holt B, Zweegman S, et al: A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 115:1113-1120, 2010
11. Morgan GJ, Gregory WM, Davies FE, et al: The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 119:7-15, 2012
12. Stewart AK, Trudel S, Bahlis NJ, et al: A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: The National Cancer Institute of Canada Clinical Trials Group Myeloma 10 Trial. Blood 121:1517-1523, 2013
13. Attal M, Lauwers-Cances V, Marit G, et al: Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366:1782-1791, 2012
14. McCarthy PL, Owzar K, Hofmeister CC, et al: Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366:1770-1781, 2012
15. Kyle RA, Rajkumar SV: Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23:3-9, 2009
16. Greipp PR, San Miguel J, Durie BG, et al: International Staging System for multiple myeloma. J Clin Oncol 23:3412-3420, 2005
17. Rajkumar SV, Harousseau JL, Durie B, et al: Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1. Blood 117: 4691-4695, 2011
18. A'Hern RP: Sample size tables for exact single-stage phase II designs. Stat Med 20:859-866, 2001
19. Kumar S, Flinn I, Richardson PG, et al: Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 119:4375-4382, 2012
20. Moreau P, Pylypenko H, Grosicki S, et al: Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study. Lancet Oncol 12:431-440, 2011
21. Palumbo A, Hajek R, Delforge M, et al: Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366:1759-1769, 2012
22. Paiva B, Vidriales MB, Cerveró J, et al: Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 112:4017-4023, 2008
23. Paiva B, Gutié rrez NC, Rosiñol L, et al: Highrisk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 119:687-691, 2012
24. Rawstron AC, Child JA, de Tute RM, et al: Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: Impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 31:2540-2547, 2013